Literature DB >> 23559342

Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis.

Pradyot Bhattacharya1, Nahid Ali.   

Abstract

Visceral leishmaniasis (VL) or kala-azar, a disseminated infection of the lymphoreticular system of the body, is marked by severe defect in immune system of the host. Successful cure of VL depends on the immune status of the host in combination with the effects of the antileishmanial drugs. The rationale approach towards eradication of this disease would be to potentiate the immune functioning of the host in addition to parasite killing. This review deals with different aspects of adaptive and innate immune responses and explores their role in protection or pathogenesis of VL. IL-10 has emerged as the principal cytokine responsible for disease pathogenesis, although evidences regarding its source during active VL remain inconclusive. On the other hand, IFNγ,under the influence of IL-12, is mostly correlated with healing of the disease. Chemokines are important in mounting cell-mediated immune response as they can prevent parasite invasion in association with cytokines. Different types of T cells like CD4, CD8 and NK T cells also contribute to the immunology of this disease. In spite of conflicting reports, the role of regulatory T cells in VL pathogenesis is important. Recently discovered Th17 subset and its different members have been reported to perform diverse functions in the course of VL and leishmaniasis as a whole. Innate immune responses, depending on the cell types, are essential in early parasite detection and subsequent development of an efficient NK cell response. Immunotherapy targeting IL-10 could be looked upon as an interesting option for the treatment of VL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23559342     DOI: 10.1590/0037-8682-0022-2012

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  18 in total

1.  Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?

Authors:  Mehrdad Hajilooi; Kosro Sardarian; Maryam Dadmanesh; Mohamad Matini; Pegah Lotfi; Ahad Bazmani; Mohammad Amin Tabatabaiefar; Mohammad Kazemi Arababadi; Mohammad Momeni
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

2.  Leishmania donovani Secretory Mevalonate Kinase Regulates Host Immune Response and Facilitates Phagocytosis.

Authors:  Tanvir Bamra; Taj Shafi; Sushmita Das; Manjay Kumar; Manas Ranjan Dikhit; Ajay Kumar; Ashish Kumar; Kumar Abhishek; Krishna Pandey; Abhik Sen; Pradeep Das
Journal:  Front Cell Infect Microbiol       Date:  2021-04-26       Impact factor: 5.293

3.  Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.

Authors:  Mohammad Asad; Pradyot Bhattacharya; Antara Banerjee; Nahid Ali
Journal:  BMC Infect Dis       Date:  2015-04-17       Impact factor: 3.090

4.  Is the polymorphism at position -1082 of IL-10 gene associated with visceral leishmaniasis?

Authors:  Mehrdad Hajilooi; Alireza Ahmadi; Pegah Lotfi; Mohammad Matini; Davood Jafari; Ahad Bazmani; Mohammad Momeni
Journal:  Iran J Public Health       Date:  2014-08       Impact factor: 1.429

Review 5.  Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Front Immunol       Date:  2014-06-26       Impact factor: 7.561

6.  Leishmania infantum amastigotes trigger a subpopulation of human B cells with an immunoregulatory phenotype.

Authors:  Guadalupe Andreani; Michel Ouellet; Rym Menasria; Alejandro Martin Gomez; Corinne Barat; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2015-02-24

Review 7.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

Review 8.  Modulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory Molecules.

Authors:  Sreenivas Gannavaram; Parna Bhattacharya; Nevien Ismail; Amit Kaul; Rakesh Singh; Hira L Nakhasi
Journal:  Front Immunol       Date:  2016-05-13       Impact factor: 7.561

9.  Visceral leishmaniasis complicating idiopathic CD4+ T-cell lymphocytopenia: 2 case reports.

Authors:  Andrew Fox-Lewis; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2017-05-11

10.  Interleukin-4 receptor alpha T1432C and A1652G polymorphisms are associated with risk of visceral leishmaniasis.

Authors:  Alireza Ahmadi; Mehrdad Hajilooi; Ghasem Solgi; Mohammad Abasi; Ahad Bazmani; Mohammad Matini; Khosro Sardarian
Journal:  Adv Biomed Res       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.